Client order highlights ongoing demand for Mycronic equipment
Mycronic (OM:MYCR) stock is in focus after the company received a replacement order for a Prexision 80 Evo mask writer worth between US$21 million and US$24 million from an existing Asian customer.
The system is scheduled for delivery in the second quarter of 2027. This points to continued interest in Mycronic’s display photomask technology and adds another sizeable unit to the company’s future delivery pipeline.
At a share price of SEK313.2, Mycronic has given investors strong momentum, with a year-to-date share price return of 44.6% and a 1-year total shareholder return of 52.27%, while the 3-year total shareholder return of 195.84% points to substantial longer-term gains, even though the 7-day share price return declined 7.39% and the 30-day share price return fell 3.33% ahead of this latest order news.
Compare Mycronic's momentum and order book with other potential opportunities by scanning the 617 high quality undiscovered gems that share strong fundamentals yet remain under the radar.
After such a strong run in Mycronic, and with the stock now close to its price target yet still trading below some estimates of intrinsic value, is most of the upside already behind you, or could there be more to go as the order book builds?
Most Popular Narrative: 0% Overvalued
On the most followed narrative, Mycronic's fair value of SEK311.5 sits almost exactly in line with the latest close at SEK313.2, which frames the recent order against a tightly priced stock.
The analysts have a consensus price target of SEK311.5 for Mycronic based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK385.0, and the most bearish reporting a price target of just SEK211.0.
This fair value hinges on a specific mix of revenue growth assumptions, margin uplift and a lower future earnings multiple than today. It also raises the question of which of those levers carries the most weight and how that aligns with Mycronic's order pipeline and guidance reset story.
Result: Fair Value of SEK311.5 (ABOUT RIGHT)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in Mycronic still need to weigh softer demand in High Flex, as well as exposure to tariffs and currency swings, which could challenge these fair value assumptions.
Find out about the key risks to this Mycronic narrative.
Another View: Mycronic and the DCF Signal
Analyst targets suggest Mycronic is roughly fairly priced around SEK311.5, while the Simply Wall St DCF model points in a different direction. At a share price of SEK313.2, Mycronic trades about 14.6% below the DCF estimate of fair value at SEK366.66, which frames recent gains in a different light.
This gap appears despite earnings forecasts that are solid rather than rapid, and a P/E of 35.2x that is higher than peers. The question for you is whether the cash flow profile justifies placing more weight on the DCF signal than on current market multiples.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Mycronic for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 258 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If the mixed signals around Mycronic leave you unsure, treat that as a cue to move quickly and test the assumptions yourself. Start by weighing the positives highlighted in the 2 key rewards.
Looking for more Mycronic investment ideas?
If Mycronic has your attention, do not stop here. Use the screener to spot other opportunities that suit your own risk, income, and valuation preferences.
- Target potential mispricing by hunting for quality companies trading below their estimated worth through the 258 high quality undervalued stocks.
- Strengthen the defensive side of your portfolio by focusing on companies with robust finances using the list of solid balance sheet and fundamentals (439 results).
- Boost your income focus by scanning higher yielding opportunities that may offer more consistent payouts through the 419 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com